Roche recognised as new Super Sector Leader in Dow Jones Sustainability Index

RocheRoche (SIX: RO, ROG; OTCQX: RHHBY) has been rated as the new Super Sector Leader in Healthcare on the Dow Jones Sustainability Index, placing Roche as the most sustainable healthcare company worldwide. Selection into the global Dow Jones Sustainability World Index as well as the pan-European Dow Jones STOXX Sustainability Index follows a thorough analysis of corporate economic, environmental and social performance, and takes into account elements such as corporate governance, risk management, access to medicines, climate change, supply chain standards, stakeholder engagement and labor practice.

Roche received maximum scores in the following categories: Research and Development, Environmental Policy/Management System and Environmental Reporting.

"Roche has been a regular member of these indexes since 2004, and while the company has always performed amongst the best, this is the first time that we are rated as the number one company," said Severin Schwan, CEO Roche Group. "Sustainability is at the core of all business practices at Roche and this recognition of our commitment is an additional incentive to continue our efforts while delivering truly innovative medicines for patients with unmet medical needs."

About the 2009 DJSI review
The 2009 analysis of sustainability leadership was performed by the SAM group, a sustainability investment specialist, together with Dow Jones Indexes and STOXX Ltd., two leading global index providers. Accounting for issues such as corporate governance, climate change, supply chain standards, and labor practices, the annual review of the DJSI family is based on a thorough assessment of corporate economic, environmental and social performance. Its results influence the investment decisions of asset managers in 16 countries who have licensed the DJSI family as benchmarks and underlying for a variety of sustainability-driven portfolios - including mutual funds, segregated accounts and structured products, as well as an exchange traded fund that is listed on Euronext. Total assets under management in DJSI-based investment vehicles currently amount to close to $6 billion.

The sector leader is the top company in each of the 19 sectors analysed, with the healthcare super sector leader being chosen from over 70 companies specialising in pharmaceuticals, medical products, healthcare providers and biotechnology.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80'€™000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

Most Popular Now

Moderna announces emergency use authorization for …

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the government of India has issued a...

Sanofi launches dedicated vaccines mRNA Center of …

Sanofi will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Center of Excellence. The Center will work to accelerate the development and d...

GSK and Alector announce global collaboration in i…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Alector (Nasdaq: ALEC), today announced a strategic global collaboration for the development and commercialisation of two clinical...

Roche's Actemra/RoActemra receives U.S. FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemr...

Positive new data for Johnson & Johnson single…

Johnson & Johnson (NYSE: JNJ) (the Company) announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly sp...

Tezepelumab granted Priority Review by U.S. FDA

Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelu...

Cancer cells eat themselves to survive

It is the membrane of cancer cells that is at the focus of the new research now showing a completely new way in which cancer cells can repair the damage that can otherwis...

mRNA vaccines slash risk of COVID-19 infection by …

People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of ...

Anti-tumor agent from the intestine

It is believed to be involved in the development of chronic inflammatory intestinal diseases, to trigger diabetes, to be responsible for obesity, even neurological diseas...

Moderna and Pfizer-BioNTech vaccines prime T cells…

Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vac...

Mefloquine: A promising drug 'soldier' in the batt…

Early 2020 saw the world break into what has been described as a "war-like situation": a pandemic, caused by the severe acute respiratory syndrome-related coronavirus 2 (...

Artificial intelligence could be new blueprint for…

Writing in the July 12, 2021 online issue of Nature Communications, researchers at University of California San Diego School of Medicine describe a new approach that uses...